Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy - Wikidata - awgldk - TriplyDB

Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy

Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy

http://www.wikidata.org/entity/Q35596724

about

Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis.Design considerations, architecture, and use of the Mini-Sentinel distributed data system.Hypertension in women of reproductive age in the United States: NHANES 1999-2008.Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population.Hypoglycemia, polycythemia and hyponatremia in a newborn exposed to nebivolol during pregnancy.The unexpected pitter patter: new-onset atrial fibrillation in pregnancy.Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures.Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis.Fetal safety of calcium channel blockers Using ICD-9 codes to establish prevalence of malformations in newborn infants.Hypertension in pregnancy: natural history and treatment options.Use of medication for cardiovascular disease during pregnancy.Cluster Headache: Special Considerations for Treatment of Female Patients of Reproductive Age and Pediatric Patients.In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review.Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.Outcomes of pregnancy in patients with known Budd-Chiari syndrome β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study.Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study.Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice.Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction.A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics

P2860

Q30618089-1B6EBC13-DB8B-472F-B3DD-6E971C64BC03 Q33863487-AF8E7EAB-BDD7-4C39-81AE-40AB6F2C16E8 Q34133833-3B019890-D697-405B-AAF4-846333314664 Q34257254-4D57825B-8678-4179-9E5F-C11B68F4BDC4 Q34298992-83719257-C452-4538-B72B-24BAB0A7A1D7 Q35056331-F525C9AD-F516-4ABB-B58E-FE79B74D24AE Q35549833-E51B9CA5-D4F7-41D8-9484-71D6A26A9F13 Q35919948-E781392A-9FB0-400A-80AA-1E133F063AA4 Q36069029-540007DE-9611-4952-9FC6-6CE87BA2996D Q36091566-0E2D27BC-27EE-4A26-A012-13401BDC2367 Q37997398-F315D259-097C-404E-9E84-6E22F51945D9 Q38400715-C0021B21-7850-436B-89BC-A6D329E4C15C Q38639052-87383A90-42CF-4799-B334-285257E33EB7 Q38681595-B995C2D2-BB51-4DA5-9948-729EAB81A495 Q38702465-688599C1-6629-47CA-8438-59EE3686D843 Q40601235-FE9C496E-79D7-4E34-8354-CC232C9F7A46 Q41264886-F6E12B40-C1CD-4A8E-82CC-4D9855830287 Q43593175-0255DA8D-ADE8-4BB0-9C46-918304F727C7 Q43842306-4AABD88B-7443-473D-985B-CA742D4BEE28 Q47325847-A436FD83-604D-4E57-AFC9-B1E9F2901FE8 Q48623943-2A9E9ABC-6058-41BE-A426-EE1682FDACEA Q50735977-A57254B4-8A9B-464F-A4C0-B6D3E4FC4589 Q58294605-8290C865-6344-48B4-A477-8C473F0D0923

P2860

Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy

http://www.wikidata.org/entity/Q35596724

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Risks of congenital malformati ...... beta-blockers during pregnancy

@ast

Risks of congenital malformati ...... beta-blockers during pregnancy

@en

type

label

Risks of congenital malformati ...... beta-blockers during pregnancy

@ast

Risks of congenital malformati ...... beta-blockers during pregnancy

@en

prefLabel

Risks of congenital malformati ...... beta-blockers during pregnancy

@ast

Risks of congenital malformati ...... beta-blockers during pregnancy

@en

P1433

Q35596724-BF40DFB8-8CDE-462C-9548-594B636312FC

P1476

Q35596724-F4FA0911-8422-4C5C-9A39-FE07D105950D

P2093

Q35596724-010EDF89-385C-4F0A-92AC-0BA95DDFF586

Q35596724-5F15DAB5-76F4-4F34-A72D-A35CB7993A58

Q35596724-6C91A85D-4FBC-4A2B-83F8-032F04330B7E

Q35596724-71A98F4F-353E-4CFE-AAED-3F1F0447CFBD

Q35596724-9A1779CF-9A1D-4436-8FA0-98C5024536FF

Q35596724-CCCA3E23-1335-4AA9-9E63-37A1000886F5

Q35596724-D7AFC0C7-72E5-4479-8A60-D0A75FD3D6C0

Q35596724-E4B5E167-BB0F-4FBB-8FF1-A899F780B240

Q35596724-FDA56D07-CDA0-4E55-8648-7A654B805193

P2860

Q35596724-02F49E9A-E32F-4950-AE04-70AB561734B8

Q35596724-26D1AA52-3F2F-4E1B-985A-70CBBF2BE652

Q35596724-328D773F-E0F9-4CC4-872A-91DC407C2DB7

Q35596724-44003EBC-A69B-4F90-8BA1-B1D98F7207AB

Q35596724-4D2AF85B-EF5B-45BF-8A70-17C88745BEE7

Q35596724-51D59ECC-FF80-44F1-97AB-17C86DCA8E03

Q35596724-65A4C5BD-98AF-4EE2-9ABE-BAC5E3E538AA

Q35596724-730C0DA5-EE9C-4CE2-8371-A33B1354FD83

Q35596724-7EFE7157-38D9-467F-B95A-C5B03FCFB733

Q35596724-99FE08EE-25C4-438E-BB91-37DCEA92A58A

P304

Q35596724-498D2B10-7E6F-4C73-A269-9C459B6E2FEF

P31

Q35596724-42A2B06C-FDC4-48F5-BD8E-3CF535853BCB

P356

Q35596724-36C9E965-4A55-4E6E-B9C5-9100E8A84E09

P433

Q35596724-DD8F8044-A7E5-4C19-8D72-6D93DA82CE44

P478

Q35596724-CC40A222-2CA2-41C5-A8BB-F333AD5DC119

P577

Q35596724-7A5F355A-77C8-49A3-98C5-1DF88A920C62

P5875

Q35596724-306ABAD6-65F9-4FF0-8270-0CBA08D27BE8

P698

Q35596724-28ACA027-B462-4F38-ACD5-F38AE840978C

P921

Q35596724-200967EE-32E4-44E0-A4BA-18694E44E75F

P932

Q35596724-4426221A-C5B7-42AB-8301-0842B543BBCB

P356

P1433

Pharmacoepidemiology and Drug Safety

P1476

Risks of congenital malformati ...... beta-blockers during pregnancy

@en

P2093

David Eastman

http://www.w3.org/2001/XMLSchema#string

David Smith

http://www.w3.org/2001/XMLSchema#string

Heather McPhillips

http://www.w3.org/2001/XMLSchema#string

Marianne Ulcickas Yood

http://www.w3.org/2001/XMLSchema#string

Marsha A Raebel

http://www.w3.org/2001/XMLSchema#string

Richard Platt

http://www.w3.org/2001/XMLSchema#string

Robert L Davis

http://www.w3.org/2001/XMLSchema#string

Sascha Dublin

http://www.w3.org/2001/XMLSchema#string

Susan E Andrade

http://www.w3.org/2001/XMLSchema#string

P2860

Oral beta-blockers for mild to moderate hypertension during pregnancy

Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data.

Fortnightly review: management of hypertension in pregnancy.

Major congenital malformations after first-trimester exposure to ACE inhibitors.

The effect of antihypertensive drugs on the fetus.

What's new in tocolytics.

Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.

Use of prescription medications with a potential for fetal harm among pregnant women.

Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study.

Therapeutic approach to hypertension during pregnancy.

P304

138-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.2068

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49773759

http://www.w3.org/2001/XMLSchema#string

P698

21254284

http://www.w3.org/2001/XMLSchema#string

P921

P932

3232183

http://www.w3.org/2001/XMLSchema#string